On Aug 12, 2021, Lykan Bioscience, a US-based contract development and manufacturing organization (CDMO) focused on cell-based therapies, and Vineti, a US-based enterprise software platform company, announced a partnership that will combine Lykan’s purpose-built, multi-product cell therapy manufacturing facility located outside Boston, Mass., and Vineti’s supply chain and data management system with the aim of optimizing cell therapy manufacturing efficiency.
Legacy systems that currently manage the production of cell therapies are often manual and outdated, which slows the scale and speed with which the therapies are produced, which can impact patient safety during development. Consequently, the cell therapy industry requires a new level of visibility, detail, and access across each product and facility within the supply chain, the companies stated in a press release.
